Bremelanotide acetate - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic drug sources for bremelanotide acetate and what is the scope of freedom to operate?
Bremelanotide acetate
is the generic ingredient in one branded drug marketed by Palatin Technologies and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Bremelanotide acetate has seventy-nine patent family members in twenty-five countries.
One supplier is listed for this compound.
Summary for bremelanotide acetate
| International Patents: | 79 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 1 |
| DailyMed Link: | bremelanotide acetate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for bremelanotide acetate
Generic Entry Date for bremelanotide acetate*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for bremelanotide acetate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Palatin Technologies, Inc | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for bremelanotide acetate
US Patents and Regulatory Information for bremelanotide acetate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Palatin Technologies | VYLEESI (AUTOINJECTOR) | bremelanotide acetate | SOLUTION;SUBCUTANEOUS | 210557-001 | Jun 21, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Palatin Technologies | VYLEESI (AUTOINJECTOR) | bremelanotide acetate | SOLUTION;SUBCUTANEOUS | 210557-001 | Jun 21, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Palatin Technologies | VYLEESI (AUTOINJECTOR) | bremelanotide acetate | SOLUTION;SUBCUTANEOUS | 210557-001 | Jun 21, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Palatin Technologies | VYLEESI (AUTOINJECTOR) | bremelanotide acetate | SOLUTION;SUBCUTANEOUS | 210557-001 | Jun 21, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for bremelanotide acetate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Palatin Technologies | VYLEESI (AUTOINJECTOR) | bremelanotide acetate | SOLUTION;SUBCUTANEOUS | 210557-001 | Jun 21, 2019 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for bremelanotide acetate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Ukraine | 118656 | ЗАСТОСУВАННЯ БРЕМЕЛАНОТИДУ У ЛІКУВАННІ ЖІНОЧОЇ СЕКСУАЛЬНОЇ ДИСФУНКЦІЇ (BREMELANOTIDE THERAPY FOR FEMALE SEXUAL DYSFUNCTION) | ⤷ Try a Trial |
| Australia | 2002322466 | ⤷ Try a Trial | |
| Australia | 783718 | ⤷ Try a Trial | |
| European Patent Office | 2916856 | UTILISATIONS DE BRÉMÉLANOTIDE DANS UNE THÉRAPIE DE DYSFONCTIONNEMENT SEXUEL FÉMININ (USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
